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Autologous induced pluripotent stem cells (iPSCs) constitute 
an unlimited cell source for patient-specific cell-based organ 
repair strategies. However, their generation and subsequent 
differentiation into specific cells or tissues entail cell line-
specific manufacturing challenges and form a lengthy process 
that precludes acute treatment modalities. These shortcom-
ings could be overcome by using prefabricated allogeneic cell 
or tissue products, but the vigorous immune response against 
histo-incompatible cells has prevented the successful imple-
mentation of this approach. Here we show that both mouse 
and human iPSCs lose their immunogenicity when major his-
tocompatibility complex (MHC) class I and II genes are inac-
tivated and CD47 is over-expressed. These hypoimmunogenic 
iPSCs retain their pluripotent stem cell potential and differ-
entiation capacity. Endothelial cells, smooth muscle cells, and 
cardiomyocytes derived from hypoimmunogenic mouse or 
human iPSCs reliably evade immune rejection in fully MHC-
mismatched allogeneic recipients and survive long-term with-
out the use of immunosuppression. These findings suggest 
that hypoimmunogenic cell grafts can be engineered for uni-
versal transplantation.
Treatment of heart disease with adult multipotent, bone mar-
row-derived stem cells has shown marginal efficacy in patients with 
acute myocardial infarction1 or chronic ischemic cardiomyopathy2,3. 
This has been attributed to the limited plasticity of adult hematopoi-
etic stem cells, which do not differentiate into cardiomyocytes and 
thus cannot replace contractile elements4. Pluripotent stem cells are 
more promising cell sources for regenerative strategies as they can 
produce an unlimited amount of progeny cells that can be differenti-
ated into functional tissue cells. Although reprogramming technol-
ogy allows the generation of autologous iPSCs for patient-specific 
treatments, this is laborious, costly, associated with uncertain qual-
ity and efficacy of individual cell products and is only practical for 
chronic diseases5–7. Thus, most regenerative approaches relying on 
autologous iPSC generation have been abandoned. Allogeneic cell 
therapies targeting large patient populations could be more eco-
nomically feasible8,9, but are subject to forceful immune rejection10. 
The use of allogeneic iPSC- or embryonic stem cell (ESC)-based 
products would require strong immunosuppression.
We envisioned engineering hypoimmunogenic pluripotent stem 
cells as a source for universally compatible cell or tissue grafts not 
requiring any immunosuppression. During pregnancy, the maternal 
immune system is tolerant of allogeneic paternal antigens although 
it would reject cells from the baby later in life11. We examined syn-
cytiotrophoblast cells, which form the interface between maternal 
blood and fetal tissue, and found low MHC class I and II expres-
sion (Supplementary Fig. 1) as well as strong expression of CD47, 
a ubiquitous membrane protein that can interact with several cell 
surface receptors to inhibit phagocytosis12. We used this knowledge 
to design hypoimmunogenic mouse iPSCs (miPSCs).
C57BL/6 wild type (WT) miPSCs13 give rise to classical tera-
tomas with ectodermal, mesodermal and endodermal features in 
SCID-beige mice (Supplementary Fig. 2). To achieve hypoimmuno-
genicity, these miPSCs underwent a three-step gene-editing process 
(Supplementary Fig. 3a). First, CRISPR guide RNAs targeting the 
coding sequence of the mouse β2-microglobulin (B2m) gene were 
ligated into vectors containing the Cas9 expression cassette and sub-
sequently transfected into miPSCs. B2m is a structural component 
of MHC class I. Second, B2m−/− miPSCs were transfected with a 
CRISPR-Cas9 vector targeting Ciita, the master regulator of MHC 
class II molecules14. Third, the Cd47 gene sequence was synthesized 
and cloned into a lentivirus with blasticidin resistance, which was 
used to transduce B2m−/−Ciita−/− miPSC clones followed by anti-
biotic selection and expansion of B2m−/−Ciita−/− Cd47 transgene 
(tg)-expressing miPSCs. WT miPSCs had interferon-γ (IFN-γ)-
inducible MHC class I surface expression, low but detectable MHC 
class II expression and negligible Cd47 expression (Supplementary 
Fig. 3b–d). We confirmed that the miPSC lines we generated lacked 
MHC class I and II expression, and over-expressed Cd47 roughly 
4.5-fold in flow cytometry. All three lines maintained their expres-
sion of pluripotency genes (Supplementary Fig. 3e–h).
Next, we transplanted WT miPSCs or engineered miPSCs into 
syngeneic C57BL/6 (H2b) and allogeneic (H2d) BALB/c recipients 
without immunosuppression. As expected, WT miPSCs showed 
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100% teratoma growth in syngeneic recipients, but all cell grafts 
were rejected in allogeneic BALB/c mice (Fig. 1a,b). After 5 days, 
splenocytes from allogeneic BALB/c recipients showed a strong 
IFN-γ and a moderate IL-4 response relative to baseline responder 
cell activity (not shown); syngeneic mice showed no responsive-
ness (Fig. 1c). Only allogeneic BALB/c recipients mounted a strong 
IgM antibody response against the WT miPSCs relative to baseline 
MFI (not shown) (Fig. 1d). Engineered miPSCs developed com-
parable teratomas to WT miPSCs in syngeneic recipients, with 
enhanced survival in allogeneic recipients that depended on their 
level of hypoimmunogenicity and increased with every engineer-
ing step (Supplementary Fig. 4a–h). Our final B2m−/−Ciita−/− Cd47 
tg miPSC line showed 100% teratoma formation and induced no 
IFN-γ or antibody responses (Fig. 1e–h).
We further evaluated the contribution of Cd47 overexpression 
by comparing B2m−/−Ciita−/− miPSCs to B2m−/−Ciita−/− Cd47 tg 
miPSCs in natural killer (NK) cell toxicity assays. Gene editing did 
not enhance the expression of stimulatory ligands for the mouse NK 
cell NKG2D or NKp46 receptors (Supplementary Fig. 4i), which 
are constitutively expressed in the NK cell-sensitive target cell line 
YAC-115. B2m−/−Ciita−/− miPSCs induced IFN-γ release that was 
significantly elevated when compared to unchallenged NK cells, 
but lower than IFN-γ release triggered by YAC-1 (Supplementary 
Fig. 4j). This suggested that Cd47 overexpression completely pre-
vented any miPSC-induced NK cell IFN-γ release in vitro. To further 
assess innate miPSC clearance in vivo, a 1:1 mixture of CFSE-labeled 
WT miPSCs and either B2m−/−Ciita−/− miPSCs or B2m−/−Ciita−/− 
Cd47 tg miPSCs were injected into the innate immune cell-rich 
peritoneum of syngeneic C57BL/6 mice (Supplementary Fig. 5a). 
Using a syngeneic host for this assay precluded relevant T cell-medi-
ated cytotoxicity. After 48 h, the peritoneal fluid was aspirated and 
CFSE-labeled cells were analyzed by flow cytometry. B2m−/−Ciita−/− 
Cd47 tg miPSCs, but not B2m−/−Ciita−/− miPSCs, were resistant to 
innate immune clearance and the 1:1 ratio with WT miPSCs could 
be maintained. We observed the same pattern of cell clearance when 
mice were pretreated with clodronate to eliminate macrophages 
(Supplementary Fig. 5b). Notably, a blocking antibody against 
mouse Cd47 completely abolished the protective effect of Cd47 in 
macrophage-depleted mice and B2m−/−Ciita−/− Cd47 tg miPSCs 
were rapidly eliminated (Supplementary Fig. 5c). Collectively, these 
data suggest an inhibitory effect of Cd47 on NK cells in vivo.
To test whether hypoimmunogenic B2m−/−Ciita−/− Cd47 tg miP-
SCs could give rise to hypoimmunogenic cardiac tissue, they were 
differentiated into endothelial cells (miECs), smooth muscle cells 
(miSMCs) and cardiomyocytes (miCMs) with WT miPSC deriva-
tives serving as controls (Supplementary Fig. 6). All derivatives 
showed the morphologic appearance, cell marker immunofluores-
cence and gene expression characteristic of their mature target tis-
sue cell lines, and cultures achieved >90% purity of VE-Cadherin+ 
miECs, Sma+ miSMCs and troponin I+ miCMs. The expression of 
MHC class I and II molecules in WT derivatives markedly varied 
by cell type (Supplementary Fig. 7a–c) but, as expected, miECs had 
by far the highest expression of IFN-γ induced MHC class I and II, 
miSMCs had moderate MHC class I and II expression16 and miCMs 
had moderate MHC class I but very low MHC class II expression17. 
All B2m−/−Ciita−/− Cd47 tg derivatives appropriately showed a com-
plete lack of MHC class I and II and significantly elevated Cd47 
compared to their WT counterparts. None of the B2m−/−Ciita−/− 
Cd47 tg derivatives showed upregulation of NKG2D or NKp46 
ligands (Supplementary Fig. 7d,e).
We next assessed the in vivo immunogenicity of WT and hypo-
immunogenic miPSCderivatives. miECs, miSMCs or miCMs 
derived from WT or B2m−/−Ciita−/− Cd47 tg were transplanted 
intramuscularly into syngeneic C57BL/6 or allogeneic BALB/c mice 
and adaptive immune responses were assessed after 5 days. All allo-
geneic recipients mounted a strong cellular IFN-γ response, as well 
as a strong IgM antibody response against all differentiated WT cell 
grafts (Supplementary Fig. 8a–c). In contrast, neither of the cor-
responding B2m−/−Ciita−/− Cd47 tg derivatives showed detectable 
increases in IFN-γ Elispot frequencies or IgM antibody production 
(Supplementary Fig. 8d–f). To assess the efficacy of Cd47 to miti-
gate the susceptibility to innate immune killing, we performed NK 
cell Elispot assays with antibody-coated magnetic bead-enriched 
BALB/c NK cells and B2m−/−Ciita−/− or B2m−/−Ciita−/− Cd47 tg deriv-
atives (Supplementary Fig. 8g–i). While B2m−/−Ciita−/− derivatives 
triggered NK cell IFN-γ release, none of the B2m−/−Ciita−/− Cd47 tg 
derivatives produced IFN-γ spot frequencies significantly exceed-
ing those of unchallenged NK cells. Accordingly, in vivo innate 
immune assays showed rapid clearance of all B2m−/−Ciita−/− deriva-
tives, but confirmed that none of the B2m−/−Ciita−/− Cd47 tg deriva-
tives showed susceptibility to innate elimination (Supplementary 
Fig. 8j–l). To confirm an inhibitory effect of Cd47 on NK cells, 
we next performed real-time in vitro killing assays with confluent 
miECs and highly purified NK cells. Both allogeneic (BALB/c) and 
syngeneic (C57BL/6) NK cells rapidly killed B2m−/−Ciita−/− miECs, 
but not WT and B2m−/−Ciita−/− Cd47 tg miECs (Supplementary 
Fig. 5d,e). However, antibody blocking of mouse Cd47 resulted in 
the rapid killing of B2m−/−Ciita−/− Cd47 tg miECs (Supplementary 
Fig. 5f). The effect of CD47 is species-specific as human NK cells 
rapidly killed both B2m−/−Ciita−/− and B2m−/−Ciita−/− Cd47 tg 
miECs (Supplementary Fig. 5g).
We next examined survival of WT and hypoimmunogenic 
miPSC derivates in vivo. WT and B2m−/−Ciita−/− Cd47 tg deriva-
tives were transduced to express firefly luciferase, and Matrigel 
plugs containing differentiated cells were transplanted into synge-
neic C57BL/6 or allogeneic BALB/c mice. All three WT derivatives 
showed long-term (50 days) survival in syngeneic C57BL/6 recipi-
ents, but were rejected in allogeneic mice (Fig. 1i–k). In contrast, all 
three B2m−/−Ciita−/− Cd47 tg derivatives showed 100% long-term 
survival in both syngeneic and allogeneic recipients (Fig. 1l–n).
Matrigel plugs containing WT or B2m−/−Ciita−/− Cd47 tg miECs 
were transplanted into allogeneic BALB/c recipients (Supplementary 
Fig. 9a). ECs are the most immunogenic cardiac cell type due to 
their high expression of MHC class I and II, which allows them 
to function as antigen-presenting cells. We observed infiltrating 
immune cells containing mostly T and B lymphocytes, but also 
some NK cells and macrophages in WT miEC plugs. B2m−/−Ciita−/− 
Cd47 tg miEC-containing plugs had almost no immune cell infil-
tration (Supplementary Fig. 9b). In the WT plugs, cytokine arrays 
on day 10 revealed an inflammatory milieu that included upregu-
lated T helper cell (Th)-1 cytokines (IFN-γ and IL-2) and Th-2 
cytokines (IL-4, IL-5, IL-10 and IL-13). In contrast, in plugs con-
taining B2m−/−Ciita−/− Cd47 tg miECs, the cytokine milieu was 
very similar to that of cell-free plugs containing only Matrigel, 
with no indication of immune activation (Supplementary Fig. 9c). 
Over time, transplanted B2m−/−Ciita−/− Cd47 tg miECs organized 
in circular structures and formed primitive vessels that contained 
erythrocytes (Supplementary Fig. 10a). Similarly transplanted 
B2m−/−Ciita−/− Cd47 tg miSMCs (Supplementary Fig. 10b) or 
miCMs (Supplementary Fig. 10c) did not form three-dimensional 
structures, and their in vivo maturation and integration potential in 
cardiac tissue remains to be studied.
We next applied our engineering strategy to human iPSCs (hiP-
SCs) using a human episomal iPSC line derived from CD34+ cord 
blood that showed a normal human XX karyotype and features of 
pluripotency (Supplementary Fig. 11a–c,g–h). The gene-editing 
process included two steps (Fig. 2a). First, both the human B2M and 
human CIITA genes were simultaneously targeted for CRISPR/Cas9-
mediated disruption. Second, these edited hiPSCs were transduced 
with a lentivirus carrying human CD47 complementary DNA with 
an EFS promotor and puromycin resistance. Antibiotic-resistant 
B2M−/−CIITA−/− CD47 tg hiPSC colonies maintained their normal 
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Fig. 1 | Survival of miPSCs and miPSC derivatives. a, WT C57BL/6 miPSCs were injected into the thigh muscle of syngeneic C57BL/6 or allogeneic 
BALB/c mice. b, Teratoma formation was observed by measuring the thigh muscle (n = 10 per group). c, IFN-γ and IL-4 enzyme-linked immunospots 
(Elispots) with splenocytes recovered 5 days after the transplantation (box 25th to 75th percentile with median, whiskers min–max, five animals per 
group, two-tailed Student’s t-test). d, Mean fluorescence imaging (MFI) of IgM binding to WT miPSCs incubated with recipient serum after 5 days (box 
25th to 75th percentile with median, whiskers min–max, six animals per group, two-tailed Student’s t-test). e, B2m−/−Ciita−/− Cd47 tg C57BL/6 miPSCs 
were transplanted into syngeneic C57BL/6 or allogeneic BALB/c recipients. f, Thigh volume C57BL/6 (n = 5) and BALB/c (n = 11) animals. The overall 
percentage of cell grafts that survived and formed teratomas in BALB/c was 100%. g, IFN-γ and IL-4 Elispots with splenocytes recovered 5 days after the 
transplantation and B2m−/−Ciita−/− Cd47 tg miPSCs stimulator cells (box 25th to 75th percentile with median, whiskers min–max, n = 6 per group, two-
tailed Student’s t-test). h, MFI of IgM binding to B2m−/−Ciita−/− Cd47 tg miPSCs incubated with recipient serum after 5 days (box 25th to 75th percentile 
with median, whiskers min–max, six animals per group, two-tailed Student’s t-test). i–n, Grafts of Fluc+ C57BL/6 miPSC derivatives in C57BL/6 or BALB/c 
recipients were longitudinally followed by bioluminescent imaging (BLI). One representative animal is depicted per group and the BLI values of all animals 
are plotted. All WT miPSC-derived miECs (i, eight animals in C57BL/6 and six animals in BALB/c), miSMCs (j, nine animals in C57BL/6 and eight animals 
in BALB/c) and miCMs (k, eight animals in C57BL/6 and seven animals in BALB/c) showed long-term survival in syngeneic C57BL/6 recipients but were 
rejected in allogeneic BALB/c animals. In contrast, all B2m−/−Ciita−/− Cd47 tg miPSC-derived miECs (l, five animals in C57BL/6 and six animals in BALB/c), 
miSMCs (m, five animals in C57BL/6 and five animals in BALB/c) and miCMs (n, five animals in C57BL/6 and five animals in BALB/c) showed long-term 
survival in both syngeneic C57BL/6 and allogeneic BALB/c recipients.
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human karyotype and pluripotency (Supplementary Fig. 11d–f,i–j) 
and successful depletion of HLA I and II surface expression, along 
with overexpression of CD47, was confirmed by flow cytometry 
(Fig. 2b). Both WT hiPSCs and B2M−/−CIITA−/− CD47 tg hiPSCs 
were differentiated into endothelial-like cells (hiECs) and cardio-
myocyte-like cells (hiCMs) (Fig. 2c). All derivatives showed the 
morphologic features and protein expression of the differenti-
ated target cells and lost their pluripotency genes (Supplementary 
Fig. 12a,b). Cultures showed >95% purity for VE-Cadherin+ hiECs 
and troponin I+ hiCMs. There were no alterations in the expression of 
stimulatory NK cell ligands with gene engineering (Supplementary 
Fig. 12c–i). WT hiECs and hiCMs upregulated IFN-γ induced HLA 
I expression roughly three- and two-fold, respectively, compared to 
WT hiPSCs and hiECs also showed roughly 11-fold elevated HLA 
II (Fig. 2d–e). B2M−/−CIITA−/− CD47 tg hiECs and hiCMs exhibited 
HLA I and II depletion and significant CD47 upregulation com-
pared to their WT counterparts.
We next performed transplant studies in humanized CD34+ 
hematopoietic stem cell-engrafted NSG-SGM3 mice18, which were 
allogeneic to the hiPSC, hiEC and hiCM grafts. Since no syngeneic 
controls are available in this humanized mouse model, background 
measurements were collected in naïve mice. After 5 days, recipi-
ents of WT hiPSCs (Fig. 2f) showed a high splenocyte IFN-γ spot 
frequency (Fig. 2g) and elevated IgM levels (Fig. 2h). Recipients of 
B2M−/−CIITA−/− CD47 tg hiPSCs did not mount any detectable cel-
lular IFN-γ response or antibody response. NK cell activation was 
assessed using in vitro incubation with human enriched CD56+ NK 
cells. B2M−/−CIITA−/− hiPSCs resulted in an IFN-γ release reach-
ing roughly one-third of the spot frequency of the highly NK cell 
susceptible K562 line, whereas B2M−/−CIITA−/− CD47 tg hiPSCs 
did not provoke any measurable response (Fig. 2i). The allogeneic 
transplantation of WT hiECs (Fig. 2j) and WT hiCMs (Fig. 2n) 
resulted in strong systemic IFN-γ reactions (Fig. 2k,o) and IgM anti-
body increases (Fig. 2l,p) of similar intensity as WT hiPSCs, whereas 
hypoimmunogenic hiECs and hiCMs did not induce any cellular or 
humoral immune response. Moreover, in vitro, hypoimmunogenic 
derivatives did not trigger NK cell activation (Fig. 2m, q) or NK cell 
killing (Supplementary Fig. 5h). As with the miPSCs, a blocking anti-
body specific for human CD47 completely abolished NK cell protec-
tion of B2M−/−CIITA−/− CD47 tg hiPSCs (Supplementary Fig. 5i).
We also assessed the survival of hiPSCs, as well as their deriva-
tives in allogeneic humanized NSG-SGM3 mice. All cell lines 
were transduced to express Fluc to enable tracking by BLI. There 
was no significant difference in HLA-A mismatch between groups 
(Supplementary Fig. 12j). As expected, all WT hiPSC grafts in 
Matrigel plugs underwent rejection (Fig. 3a) and all B2M−/−CIITA−/− 
CD47 tg hiPSCs formed teratomas. Similarly, WT hiECs (Fig. 3b) 
and WT hiCMs (Fig. 3c) were rejected, although at slightly slower 
rate than in the corresponding miPSC derivative experiments. This 
difference may be based on the reduced number, diversity and func-
tion of human immune cells in mouse recipients19, although the 
triple transgenic NSG-SGM3 mice specifically express human cyto-
kines20 to minimize these limitations. All B2M−/−CIITA−/− CD47 
tg hiEC and hiCM grafts showed long-term survival (50 days) and 
stable BLI signal levels over time. The hiECs gradually organized 
into structures resembling primitive vascular structures, which 
occasionally contained erythrocytes, and the hiCMs acquired a lim-
ited polarized architecture (Fig. 3d,e).
hiECs, the most immunogenic derivatives, were further tested 
in the humanized BLT mouse model. BLT humanized mice are 
bioengineered by implantation of human fetal liver and thymic tis-
sue under the kidney capsule followed by intravenous transplanta-
tion with autologous CD34+ HSCs21 (Fig. 3f). This allows for T cell 
maturation in human thymic tissue and permits HLA restricted 
T cell responses. WT hiEC grafts in Matrigel plugs triggered a 
roughly 40% stronger IFN-γ response but 40% weaker IgM antibody 
response than in the previous NSG-SGM3 mice. No measurable 
immune activation was detected in recipients of B2M−/−CIITA−/− 
CD47 tg hiEC grafts (Fig. 3g,h). All WT hiEC grafts underwent 
rapid rejection while four out of five B2M−/−CIITA−/− CD47 tg 
hiEC grafts achieved survival (Fig. 3i). We assume a non-immune-
related reason for the failure of the fifth graft since no immune 
activation could be detected in this specific recipient. We thus 
demonstrated that the combination of MHC class I and II deple-
tion and CD47 overexpression renders both mouse and human 
stem cells, as well as their differentiated derivatives, hypoimmuno-
genic. In the models studied here, engineered differentiated deriva-
tives achieved long-term survival in fully allogeneic hosts without 
any immunosuppression and retained basic cell-specific features 
after transplantation.
The initial concept of hypoimmunogenic pluripotent stem cells 
was based on an MHC class I knockdown and showed encouraging 
early results22. However, according to the ‘missing-self theory’, MHC 
class I-deficient mouse and human PSCs become susceptible to NK 
Fig. 2 | immune response against hiPSC derivatives. a, WT hiPSCs first underwent B2M and CIITA gene disruption and then CD47 transgene 
overexpression b, Gene editing of hiPSCs was confirmed by flow cytometry (box 25th to 75th percentile with median, whiskers min–max, four independent 
experiments per graph, analysis of variance (ANOVA) with Bonferroni’s post-hoc test). c, WT and B2M−/−CIITA−/− CD47 tg hiPSCs were differentiated 
into both hiECs and hiCMs. d–e, The immune phenotype of WT and B2M−/−CIITA−/− CD47 tg hiECs (d) and hiCMs (e) is shown (box 25th to 75th 
percentile with median, whiskers min–max, four independent experiments per graph, two-tailed Student’s t-test). f, WT or B2M−/−CIITA−/− CD47 tg hiPSC 
grafts were injected into allogeneic humanized NSG-SGM3 mice. g, IFN-γ Elispots were performed after 5 days (mean ± s.d., n = 7 per group, two-tailed 
Student’s t-test), the background spot frequency in naïve mice is shown (mean ± s.d., four animals per group, two-tailed Student’s t-test). h, MFI of IgM 
binding to either hiPSC incubated with recipient serum after 5 days (mean ± s.d., five animals per group, two-tailed Student’s t-test), the background 
fluorescence in naïve mice is shown (mean ± s.d., three animals per group, Student’s t-test). i, IFN-γ Elispots with human NK cells were performed with 
B2M−/−CIITA−/− hiPSC or B2M−/−CIITA−/− CD47 tg hiPSC (box 25th to 75th percentile with median, whiskers min–max, six independent experiments, 
ANOVA with Bonferroni’s post-hoc test). j, WT or B2M−/−CIITA−/− CD47 tg hiEC grafts were injected into allogeneic humanized NSG-SGM3 mice. k, IFN-γ 
Elispots were performed after 5 days (mean ± s.d., three animals per group, two-tailed Student’s t-test), the background spot frequency in naïve mice is 
shown (mean ± s.d., four animals per group, two-tailed Student’s t-test). l, MFI of IgM binding to either hiEC incubated with recipient serum after 5 days 
(mean ± s.d., three animals per group, two-tailed Student’s t-test), the background fluorescence in naïve mice is shown (mean ± s.d., three animals per 
group, Student’s t-test). m, IFN-γ Elispots with human NK cells were performed with B2M−/−CIITA−/− hiECs or B2M−/−CIITA−/− CD47 tg hiECs (box 25th to 
75th percentile with median, whiskers min–max, six independent experiments, ANOVA with Bonferroni’s post-hoc test). n, WT or B2M−/−CIITA−/− CD47 
tg hiCM grafts were injected into allogeneic humanized NSG-SGM3 mice. o, IFN-γ Elispots were performed after 5 days (mean ± s.d., three animals per 
group, two-tailed Student’s t-test), the background spot frequency in naïve mice is shown (mean ± s.d., four animals per group, two-tailed Student’s t-
test). p, MFI of IgM binding to either hiCM incubated with recipient serum after 5 days (mean ± s.d., three animals per group, two-tailed Student’s t-test), 
the background fluorescence in naïve mice is shown (mean ± s.d., three animals per group, Student’s t-test). q, IFN-γ Elispots with human NK cells were 
performed with B2M−/−CIITA−/− hiCMs or B2M−/−CIITA−/− CD47 tg hiCMs (box 25th to 75th percentile with median, whiskers min–max, six independent 
experiments, ANOVA with Bonferroni’s post-hoc test).
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cell killing23–25. Although isolated expression of HLA-E26 or HLA-G27 
in human pluripotent stem cells has been used to mitigate NK cell 
cytotoxicity, we observed that CD47 is a very effective non-MHC 
ligand to silence all innate immune responses. However, cells elud-
ing immune monitoring may pose the long-term risks of uncon-
trollable malignant transformation or impaired virus clearance, 
although for the latter alternative mechanisms have been shown28. 
Inducible kill switches could enhance their overall safety.
The ability to generate substantial amounts of cardiac tissue 
from allogeneic iPSC-derived CMs has been well demonstrated 
in macaques29. However, the amounts of toxic immunosuppres-
sive drugs required to achieve allogeneic cell survival pose a major 
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Fig. 3 | Survival of hiPSCs and hiPSC derivatives in allogeneic hosts. Grafts of Fluc+ WT or B2M−/−CIITA−/− CD47 tg hiPSCs, hiECs and hiCMs were 
transplanted into allogeneic humanized mice (NSG-SGM3 mice in a–e, BLT mice in f–i) and were longitudinally followed by BLI. One representative 
animal is depicted per group and the BLI values of all animals are plotted. a, BLI signals over time of WT and B2M−/−CIITA−/− CD47 tg hiPSC grafts (n = 5 
per group). b, WT and B2M−/−CIITA−/− CD47 tg hiECs were transplanted as in a (n = 5 per group). c, WT and B2M−/−CIITA−/− CD47 tg hiCMs (n = 5). d, 
B2M−/−CIITA−/− CD47 tg hiECs started to organize into a more complex structure, which included primitive vascular structures (representative pictures 
of three independent experiments). Scale bar, 50 μm. e, The B2M−/−CIITA−/− CD47 tg hiCMs began to organize into a more polarized framework and 
maintained their sarcomeric alpha-actinin cytoskeletal structure typical of cardiomyocytes (representative pictures of three independent experiments). 
Scale bar, 50 μm. f, WT or B2M−/−CIITA−/− CD47 tg hiECs were transplanted into allogeneic humanized BLT mice. g, IFN-γ Elispots were performed after 
5 days (box 25th to 75th percentile with median, whiskers min–max, four animals per group, two-tailed Student’s t-test), the background spot frequency 
in naïve mice is shown. h, MFI of IgM binding to either hiEC incubated with recipient serum after 5 days (mean ± s.d., four animals per group, two-tailed 
Student’s t-test), the background fluorescence in naïve mice is shown (mean ± s.d., three animals per group, two-tailed Student’s t-test). i, Grafts of Fluc+ 
WT or B2M−/−CIITA−/− CD47 tg hiECs were transplanted into allogeneic humanized BLT mice and were longitudinally followed by BLI. All WT hiEC grafts 
were rejected within roughly 14 days (four animals). Four of the five B2M−/−CIITA−/− CD47 tg hiEC grafts permanently survived, the one failure is believed 
not to be immune-mediated (five animals).
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hurdle for clinical use. Even with fully MHC class I- and II-matched 
allogeneic iPSC-derived CM grafts, macaque recipients required 
substantial and highly toxic immunosuppression to prevent cell 
rejection29,30. Thus, the generation of universal hypoimmunogenic 
iPSCs that can be differentiated into the main components of cardiac 
tissue and achieve long-term survival in a fully allogeneic recipient 
without any immunosuppression may help to develop universal cell 
products to treat heart failure.
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Methods
Syncytiotrophoblast cells of mouse placenta. On isolated mouse 
syncytiotrophoblast cells, expression of MHC class I, MHC class II and Cd47  
was performed using PCR. RNA was isolated with the RNeasy Plus Mini kit 
(Qiagen) according to the manufacturer’s protocol. RT–PCR was performed  
to generate the cDNA (Applied Biosystems). The following primers were used: 
mouse MHC class I: 5′-AGTGGTGCTGCAGAGCATTACAA-3′, reverse:  
5′-GGTGACTTCACCTTTAGATCTGGG-3′, MHC class II forward: 
5′-GATGTGGAAGACCTGCG-3′, reverse: 5′-TGCATCTTCTGAGGGGTTTC-3′; 
mouse Cd47 forward: 5′-GGCGCAAAGCACCGAAGAAATGTT-3′, reverse: 
5′-CCATGGCATCGCGCTTATCCATTT-3′. PCRs were performed on 
Mastercycler nexus (Eppendorf) and the amplification products were visualized  
by 2% agarose gel electrophoresis (Thermo Fisher).
Derivation of mouse iPSCs. Mouse tail tip fibroblasts of mice were dissociated 
and isolated with collagenase type IV (Life Technologies) and maintained with 
Dulbecco’s modified Eagle medium (DMEM) containing 10% fetal bovine serum 
(FBS), 1% glutamine, 4.5 g l−1 glucose, 100 U ml−1 penicillin, and 100 μg ml−1 
streptomycin (pen-strep) at 37 °C, 20% O2, and 5% CO2 in a humidified incubator. 
1 × 106 mouse fibroblasts were then re-programmed using a mini-intronic 
plasmid carrying sequences of Oct4, Klf4, Sox2 and c-Myc as well as short hairpin 
RNA against p53 (10–12 μM of DNA) using the Neon Transfection system13. 
After transfection, fibroblasts were plated on mitomycin-inhibited CF1 mouse 
embryonic fibroblasts (MEF, Applied Stemcell) and kept in fibroblast media with 
the addition of sodium butyrate (0.2 mM) and 50 μg ml−1 ascorbic acid. When 
ESC-like colonies appeared, media was changed to mouse iPSC media containing 
DMEM + GlutaMax 31966 (Gibco) with 10% heat-inactivated fetal calf sera (FCS 
hi), 1% MEM-NEAA and 1% pen-strep (all Gibco). With every passage, the iPSCs 
were sorted for the mouse pluripotency marker SSEA-1 using antibody-coated 
magnetic bead based cell sorting.
Mouse iPSC culture. After the MEF feeder cells attached and were 100% 
confluent, miPSCs were grown on MEF in knockout DMEM 10829 with 15% 
knockout Serum Replacement, 1% glutamine, 1% MEM-NEAA, 1% pen-strep 
(all Gibco), 0.2% beta-mercaptoethanol and 100 units LIF (both Millipore). Cells 
were maintained in 10 cm dishes, medium was changed daily and the cells were 
passaged every 2–3 days using 0.05% trypsin-EDTA (Gibco). miPSCs were cultured 
on gelatin (Millipore) without feeders before experiments using the standard 
media. Cell cultures were regularly screened for mycoplasma infections using the 
MycoAlert Kit (Lonza).
Pluripotency analysis by RT–PCR and immunofluorescence. miPSC were  
plated in confocal dishes (MatTek) for immunofluorescence analysis 48 h after 
plating using the miPSC Characterization kit (Applied Stemcell). Briefly, cells were 
fixed, permeabilized, and stained overnight at 4 °C with the primary antibodies 
for Sox2, SSEA-1 and Oct4. After several washes the cells were incubated with a 
secondary antibody and DNA staining solution. Alkaline phosphatase activity 
assay was performed (Applied Stemcell). Stained cells were imaged using a 
fluorescent microscope.
For RT–PCR, RNA was extracted using the RNeasy Plus Mini Kit (Qiagen). 
Genomic DNA contamination was removed using the gDNA spin column. 
cDNA was generated using Applied Biosystems High-Capacity cDNA Reverse 
Transcription kit. Gene-specific primers of the miPSC Characterization Kit (Applied 
Stemcell) were used to amplify target sequences. Actin was used as housekeeping 
gene, which encodes a cellular cytoskeleton protein. PCR reactions were performed 
on Mastercycler nexus (Eppendorf) and visualized on 2% agarose gels.
Pluripotency analysis by in vivo teratoma assay. Ten million miPSCs were 
injected intramuscular into the hind limb of immunodeficient SCID-beige mice 
and teratoma development was observed within 14 days. Teratomas were recovered 
and fixed in 4% paraformaldehyde in PBS, dehydrated, embedded in paraffin, and 
cut into sections of 5 µm thickness. For histopathology, sections were rehydrated 
and stained with hematoxylin and eosin (Carl Roth). Images were taken with an 
inverted light microscope.
Immunofluorescence staining demonstrated differentiation into ectodermal, 
mesodermal, and endodermal cells using antibodies against brachyury (ab20680, 
Abcam), cytokeratin 8 (ab 192467) and GFAP (GA5, Cell Signaling). For 
visualization, secondary antibodies conjugated with Alexa Fluor 555, 488 and 
647 (all Invitrogen) were used, respectively. Cell nuclei were counterstained with 
4,6-diamidino-2-phenylindole (DAPI) and imaging was performed with a Leica 
SP5 laser confocal microscope (Leica).
Gene editing of mouse iPSCs. miPSCs underwent three gene-modification 
steps. First, CRISPR guides targeting the coding sequence of mouse B2m gene 
were annealed and ligated into vectors containing the Cas9 expression cassette. 
Transfected miPSCs were dissociated to single cells, expanded to colonies, 
sequenced and tested for homogeneity. Second, these B2m−/− miPSCs were 
transfected with vectors containing CRISPR guides targeting Ciita. Expanded 
single cell colonies were sequenced and B2m−/−Ciita−/− clones were identified 
through the presence of aberrant sequence from the CRISPR cleavage site. Third, 
the Cd47 gene sequence was synthesized and the DNA was cloned into a lentiviral 
with blasticidin resistance. B2m−/−Ciita−/− miPSCs were transduced with the 
resulting lentivirus and grown in the presence of blasticidin. Antibiotic-selected 
pools were tested for Cd47 overexpression and B2m−/−Ciita−/− Cd47 tg miPSCs 
were expanded.
Generation of B2m−/− miPSCs. CRIPSR technology was used for disruption of 
the B2m gene. For targeting the coding sequence of mouse B2m gene, the CRISPR 
sequence 5′-TTCGGCTTCCCATTCTCCGG(TGG)-3′ was annealed and ligated 
into the All-In-One (AIO) vectors containing the Cas9 expression cassette as per 
the kit’s instructions (GeneArt CRISPR Nuclease Vector Kit, Thermo Fisher). 
miPSC were transfected with the AIO vectors using Neon electroporation with two 
1,200 V pulses of 20 ms duration. The transfected iPSC cultures were dissociated 
to single cells using 0.05% trypsin (Gibco) and then sorted with FACSAria cell 
sorter (BD Bioscience) for removing doublets and debris by selective gating on 
forward and side light scatter properties. Single cells were expanded to full-size 
colonies and tested for CRISPR editing by screening for the presence of the 
altered sequence from the CRISPR cleavage site. Briefly, the target sequence was 
amplified via PCR using AmpliTaq Gold Master Mix (Applied Biosystems) and 
the primers B2m gDNA forward: 5′-CTGGATCAGACATATGTGTTGGGA-3′, 
reverse: 5′-GCAAAGCAGTTTTAAGTCCACACAG-3′. After cleanup of the 
obtained PCR product (PureLink Pro 96 PCR Purification Kit, Thermo Fisher), 
Sanger sequencing was performed. The Ion Personal Genome Machine (PGM) 
Sequencing was used for the identification of the homogeneity, through sequencing 
of a PCR amplified 250 base pair region of the B2m gene using primers B2m gDNA 
PGM forward: 5′-TTTTCAAAATGTGGGTAGACTTTGG-3′ and reverse: 5′- 
GGATTTCAATGTGAGGCGGGT-3′. The PCR product was purified as described 
above and prepared using the Ion PGM Hi-Q Template Kit (Thermo Fisher). 
Experiments were performed on the Ion PGM System with the Ion 318 Chip Kit 
v.2 (Thermo Fisher).
Generation of B2m−/−Ciita−/− miPSCs. CRIPSR technology was used for the 
further disruption of the Ciita gene. For targeting the coding sequence of mouse 
Ciita gene, the CRISPR sequence 5’- GGTCCATCTGGTCATAGAGG (CGG)-
3′ was annealed and ligated into the All-In-One (AIO) vectors containing the 
Cas9 expression cassette as per the kit’s instructions (GeneArt CRISPR Nuclease 
Vector Kit, Thermo Fisher). miPSC were transfected with the AIO vectors using 
the same condition for B2m disruption. The transfected miPSC cultures were 
dissociated to single cells using 0.05% trypsin (Gibco) and then sorted with 
FACSAria cell sorter (BD Bioscience) for removing doublets and debris by selective 
gating on forward and side light scatter properties. Single cells were expanded to 
full-size colonies and tested for CRISPR editing by screening for the presence of 
an altered sequence from the CRISPR cleavage site. Briefly, the target sequence 
was amplified via PCR using AmpliTaq Gold Master Mix (Applied Biosystems) 
and the primers Ciita gDNA forward: 5′-CCCCCAGAACGATGAGCTT-3′, 
reverse: 5′-TGCAGAAGTCCTGAGAAGGCC-3′. After cleanup of the obtained 
PCR product (PureLink Pro 96 PCR Purification Kit, Thermo Fisher), Sanger 
sequencing was performed. Using the DNA sequence chromatogram, edited clones 
were then identified through the presence of altered sequence from the CRISPR 
cleavage site. Indel size was calculated using the TIDE tool. PCR and ICC were 
performed again to verify the pluripotency status of the cells.
Generation of B2m−/−Ciita−/− Cd47 tg miPSCs. Cd47 transgene overexpression 
was generated using lentivirus-mediated delivery of a Cd47-expressing vector 
containing the antibiotic resistance cassette blasticidin. The Cd47 cDNA was 
synthesized and cloned into the lentiviral plasmid pLenti6/V5 (Thermo Fisher) 
with a blasticidin resistance. Sanger sequencing was performed to verify that no 
mutation had occurred. Lentivirus generation was performed with a stock titer 
of 1 × 107 TU per ml. The transduction was performed into 2 × 105 B2m−/−Ciita−/− 
miPSCs, grown on blasticidin-resistant MEF cells for 72 h with a MOI ratio of  
1:10 followed by antibiotic selection with 12.5 μg ml−1 blasticidin for 7 days. 
Antibiotic-selected pools were tested by RT–quantitative PCR amplification of 
Cd47 mRNA and flow cytometry detection of Cd47 on the surface of the cells. 
After the confirmation of Cd47, cells were expanded and validated by running 
pluripotency assays.
Transduction to express firefly luciferase. iPSCs were transduced to express Fluc. 
One hundred thousand miPSCs were plated in one gelatin-coated six-well plates 
and incubated overnight at 37 °C at 5% CO2. The next day, media was changed 
and one vial of Fluc lentiviral particles expressing luciferase II gene under re-
engineered EF1a promotor (GenTarget) was added to 1.5 ml media. After 36 h, 
1 ml of cell media was added. After further 24 h, complete media change was 
performed. After 2 days, luciferase expression was confirmed by adding D-luciferin 
(Promega). Signals were quantified with IVIS 200 (Perkin Elmer) in maximum 
photons s−1 cm−2 sr–1
Karyotyping. Cell collection, slide preparation and G-banded karyotyping were 
performed using standard cytogenetics protocols optimized for human pluripotent 
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cells. Cells were incubated with ethidium bromide and colcemid (Gibco) and then 
trypsinized to detach the cells from the plate. The cells were placed in hypotonic 
solution (0.075 M potassium chloride, 0.559 g KCl in 100 ml water, Millipore), 
followed by fixation. Metaphase cell preparations were stained with Leishman’s 
stain. Karyotype analysis consisted of chromosomes counted in twenty cells with 
band-by-band analysis of eight cells.
Mice. BALB/c (BALB/cAnNCrl, H2d), C57BL/6 (C57BL/6 J, H2b) and SCID-beige 
(CBySmn.CB17-Prkdcscid/J) (all 6–12 weeks) were used as recipients for different 
assays. The number of animals per experimental group is presented in each figure. 
Mice were purchased from Charles River Laboratories (Sulzfeld) and received 
humane care in compliance with the Guide for the Principles of Laboratory 
Animals. Animal experiments were approved by the Hamburg ‘Amt für Gesundheit 
und Verbraucherschutz’ or the University of California San Francisco (UCSF) 
Institutional Animal Care and Use Committee and performed according to local 
and EU guidelines.
Teratoma assays to study miPSC survival in vivo. Six-to-eight-week-old 
syngeneic or allogeneic mice were used for transplantation of WT miPSCs or 
hypoimmunogenic miPSCs. Two million cells were injected in 60 µl saline into the 
right thigh muscle of the mice. Tumor growth was measured with a caliper every 
other day until day 30 and from day 30 to day 80 every tenth day. They were killed 
after development of tumors larger than 1.5 cm3 or following an observation period 
of 80 days.
Derivation and characterization of miPSC-derived endothelial cells (miECs). 
miPSC were plated on gelatin in six-well plates and maintained in mouse iPSC 
media. After the cells reached 60% confluency, the differentiation was started and 
media was changed to RPMI-1640 containing 2% B-27 minus Insulin (both Gibco) 
and 5 μM CHIR-99021 (Selleckchem). On day 2, the media was changed to reduced 
media: RPMI-1640 containing 2% B-27 minus Insulin (both Gibco) and 2 μM 
CHIR-99021 (Selleckchem). From day 4 to day 7, cells were exposed to RPMI-1640 
EC media, RPMI-1640 containing 2% B-27 minus Insulin plus 50 ng ml−1 mouse 
vascular endothelial growth factor (mVEGF; R&D Systems), 10 ng ml−1 mouse 
fibroblast growth factor basic (mFGFb; R&D Systems), 10 μM Y-27632 (Sigma-
Aldrich) and 1 μM SB 431542 (Sigma-Aldrich). Endothelial cell clusters were 
visible from day 7 and cells were maintained in EGM-2 SingleQuots media (Lonza) 
plus 10% FCS hi (Gibco), 25 ng ml−1 mVEGF, 2 ng ml−1 mFGFb, 10 μM Y-27632 
(Sigma-Aldrich) and 1 μM SB 431542. The differentiation process was completed 
after 21 days and undifferentiated cells detached during the differentiation process. 
For purification, cells went through magnetic-activated cell separation (MACS) 
purification according the manufacturer’s protocol using anti-CD15 mAb-coated 
magnetic microbeads (Miltenyi) for negative selection.
The highly purified miECs in the flow-through were cultured in EGM-2 
SingleQuots media plus supplements and 10% FCS hi. TrypLE was used 
for splitting the cells 1:3 every 3–4 days. Their phenotype was confirmed by 
immunofluorescence for CD31 (ab28364, Abcam) and VE-Cadherin (sc-6458, 
Santa Cruz Biotechnology). Briefly, cells were fixed with 4% paraformaldehyde 
in PBS for 15 min. Cell membranes were permeabilized with Permeabilization 
solution (ASB-0102, Applied StemCell), followed by Blocking solution (ASB-0103, 
Applied StemCell) and incubation with the primary antibodies. For visualization, 
cells were incubated with secondary antibody conjugated with AF488 or AF555 
(Invitrogen). After nuclei staining with DAPI, images were obtained and analyzed 
with a Leica SP5 laser confocal microscope (Leica).
Tube formation assay was performed for miEC characterization: 2.5 × 105 
miECs were stained with 5 µM CFSE and 0.1 μg ml−1 Hoechst (both Thermo Fisher) 
for 10 min at room temperature and plated on 10 mg ml−1 undiluted Matrigel 
(356231, Corning) in 24-well plates. After 48 h, tube formations were visualized 
by immunofluorescence. PCR was performed as described above. The following 
primers were used: VE-Cadherin forward: 5′-GGATGCAGAGGCTCACAGAG-3′, 
reverse: 5′-CTGGCGGTTCACGTTGGACT-3′.
Derivation and characterization of miPSC-derived smooth muscle cells 
(miSMCs). The resuspended miPSCs were cultivated on six-well, 0.1% gelatin-
coated plastic petri dishes (Falcon, Becton–Dickinson) at 2 × 106 cells per well 
at 37 oC, 5% CO2 in 2 ml of differentiation medium with the presence of 10 μM 
all-trans-retinoic acid. The differentiation medium was made of DMEM, 15% 
FCS, 2 mM L-glutamine, 1 mM methyl thioglycolate (MTG) (Sigma-Aldrich), 1% 
non-essential amino acids and pen-strep. The culture was continued for 10 days 
with daily media changes. Starting from the 11th day, the differentiation medium 
was replaced by serum-free culture medium, which was composed of knock-out 
DMEM, 15% knock-out serum replacement, 2 mM L-glutamine, 1 mM MTG, 
1% non-essential amino acids and pen-strep. The cultures were continued for 
another 10 days with daily change of the serum-free medium. For purification, 
cells were enriched according the manufacturer’s protocol using anti-CD15 
mAb-coated magnetic microbeads (Miltenyi) for negative selection. The flow-
through containing enriched miSMCs were cultured in RMPI-1640 Glutamax 
plus 20% FCS hi and 1% pen-strep (all Gibco). Their phenotype was confirmed by 
immunofluorescence and PCR for both Sma and Sm22.
Immunofluorescence staining was performed as described above. Primary 
antibodies were used against smooth muscle actin (ab21027, Abcam) and sm22 
(ab14106, Abcam), followed by the corresponding secondary antibody conjugated 
with AF488 or AF555 (Invitrogen).
PCR was performed as described above. The following primers 
were used: SMA forward: 5′-CGGCTTCGCTGGTGATGAT-3′, 
reverse: 5′-CATTCCAACCATTACTCCCTGAT-3′; SM22 
forward: 5′-AACAGCCTGTACCCTGATGG-3′, reverse: 
5′-CGGTAGTGCCCATCATTCTT-3′.
Derivation and characterization of miPSC-derived cardiomyocytes (miCMs). 
Before differentiation, miPSCs were passaged two times on gelatin-coated flasks 
to remove the feeder cells. At day 0, differentiation was started with 80,000 cells 
per ml in IMEM/Ham’s F12 (3/1, both Corning) +0.5% N2-Supplement, 1% B27 
retinoic acid, 0.05% BSA, 1% pen-strep, 1% glutamine (Gibco), 5 mg ml−1 ascorbic 
acid and 40 ng ml−1 MTG (both Sigma-Aldrich) for 2 days in uncoated 10 cm plates. 
At day 2, cells were transferred in IMEM/Ham’s F12 (3/1, both Corning) with 0.5% 
N2-Supplement, 1% B27 retinoic acid, 0.05% BSA, 1% pen-strep, 1% glutamine (all 
Gibco), 5 mg ml−1 ascorbic acid and 40 ng ml−1 MTG (Sigma-Aldrich) for 2 days in 
uncoated 10 cm plates. On day 4, cells were plated in gelatin-coated six-well plates 
in SP34 media containing 1% glutamine, 50 μg ml−1 ascorbic acid, 5 ng ml−1 VEGF, 
500 μg ml−1 hFGFb and 25 ng ml−1 hFGF10 (R&D Systems). Media was changed 
on day 7 to SP34 media containing 1% glutamine and 50 μg ml−1 ascorbic acid 
and was changed every other day. Beating of cells started around days 11–14 and 
demonstrated their function.
For enrichment, cells separated by MACS according the manufacturer’s 
protocol using anti-CD15 mAb-coated magnetic microbeads (Miltenyi) for 
negative selection. The flow-through containing enriched miCMs were replated 
and used for different assays.
Immunofluorescence staining was performed as described above to confirm 
their phenotype. Primary antibodies were used against α-sarcomeric actinin 
(EA-53, Abcam) or troponin I (ab47003, Abcam) followed by the corresponding 
secondary antibody conjugated with AF488 or AF555 (Invitrogen).
PCR for Gata4 forward: 5′-CTGTCATCTCACTATGGGCA-3′, 
reverse: 5′-CCAAGTCCGAGCAGGAATTT-3′ and Mhy6 
forward: 5′-ATCATTCCCAACGAGCGAAAG-3′, reverse: 
5′-AAGTCCCCATAGAGAATGCGG-3′ was performed as described above.
Flow cytometry analysis. For the detection of MHC class I and II surface 
molecules on miPSCs, miECs, miSMCs and miCMs, cells were plated on gelatin-
coated six-well plates in medium containing 100 ng ml−1 of IFN-γ. After collection, 
cells were labeled with antibodies. For MHC class I: PerCP-eFlour710-labeled 
anti-MHC class I antibody (clone AF6-88.5.5.3, eBioscience) or PerCP-eFlour710-
labeled mouse IgG2b isotype-matched control antibody (clone eB149/10H5, 
eBioscience). The anti-MHC class I antibody reacts with the H-2Kb MHC class 
I alloantigen. For MHC class II: PerCP-eFlour710-labeled anti-MHC class II 
antibody (clone M5/114.15.2, eBioscience) or PerCP-eFlour710-labeled mouse 
IgG2a isotype-matched control antibody (clone eBM2a, eBioscience). The MHC 
class II antibody reacts with the mouse MHC class II, both I-A and I-E subregion-
encoded glycoproteins. Cd47: Alexa Fluor 647-labeled anti-mouse Cd47 antibody 
(clone miap301, BD Biosciences) or Alexa Fluor 647-labeled mouse IgG2a  
isotype-matched control antibody (clone R35-95, BD Biosciences). The anti- 
Cd47 antibody specifically binds to the extracellular domain of mouse Cd47, also 
known as Integrin-Associated Protein. Cells were analyzed by flow cytometry  
(BD Bioscience) and results were expressed as fold change to isotype-matched 
control Ig staining.
For the assessment of purity of miPSC derivatives, antibodies against  
SSEA-1 (Thermo Fisher), VE-Cadherin (Sigma), SMA (Abcam) and Troponin I 
(Santa Cruz) were used. The miECs, miSMCs and miCMs were generated with a 
purity of >90%.
Elispot assays. For uni-directional Elispot assays, recipient splenocytes were 
isolated from spleen 5 days after cell injection and used as responder cells. Donor 
cells were mitomycin-treated (50 μg ml−1 for 30 min) and used as stimulator cells. 
One hundred thousand stimulator cells were incubated with 1 × 106 recipient 
responder splenocytes for 24 h and IFN-γ and IL-4 spot frequencies were 
enumerated using an Elispot plate reader.
Donor-specific antibodies. Sera from recipient mice were de-complemented by 
heating to 56 °C for 30 min. Equal amounts of sera and cell suspensions (5 × 106 ml) 
were incubated for 45 min at 4 °C. Cells were labeled with FITC-conjugated goat 
anti-mouse IgM (Sigma-Aldrich) and analyzed by flow cytometry (BD Bioscience).
Mouse NK cell Elispot assays in vitro. NK cells were isolated from fresh BALB/c 
spleen 18 h after poly I:C injection (150 ng poly I:C in 200 μl sterile saline, 
intraperitoneally, Sigma-Aldrich). After red cell lysis, cells were purified by anti-
CD49b mAb-coated magnetic bead-sorting and were used as responder cells. 
This cell population was >99% CD3- and contains NK cells (>90%) and other 
cells including myeloid cells (<10%). Using the Elispot principle, NK cells were 
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co-cultured with B2m−/−Ciita−/− or B2m−/−Ciita−/− Cd47 tg miPSCs in the presence 
of IL-2 (1 ng ml−1, Peprotech) and their IFN-γ release was measured. YAC-1 cells 
(Sigma-Aldrich) served as positive control. Mitomycin-treated (50 μg ml−1 for 
30 min) stimulator cells were incubated with NK cells (1:1) for 24 h and IFN-γ spot 
frequencies were enumerated using an Elispot plate reader.
Mouse in vivo innate cytotoxicity assay. Five million WT miPSCs and 5 × 106 
B2m−/−Ciita−/− miPSCs or 5 × 106 B2m−/−Ciita−/− Cd47 tg miPSCs were mixed  
and stained with 5 μM CFSE. Cells in saline with IL-2 (1 ng ml−1, Peprotech)  
were injected intraperitoneally into syngeneic C57BL/6 mice. After 48 h, cells  
were collected from the abdomen and stained with PerCP-eFlour710 labeled  
anti-MHC class I mAb for 45 min at 4 °C. The CFSE-positive and MHC class 
I-negative population was analyzed by flow cytometry (BD Bioscience) and 
compared between the WT and the engineered miPSC group. The assay was 
performed with miPSCs, miECs, miSMCs and miCMs. Some animals were 
pretreated with clodronate (200 μl intraperitoneally 3 days before the experiment; 
Liposoma) to eliminate macrophages and make the assay more specific for NK 
cells. Some animals were pretreated with in vivo Cd47-blocking antibody (BE0270, 
100 μg intraperitoneally, 7 days and 3 days before the experiment; BioXCell) to 
eliminate Cd47.
NK cell stimulatory ligands. For the detection of NK cell stimulatory ligands on 
miPSCs, miECs, miSMCs and miCMs, cells were blocked with mouse FcR blocking 
reagent (Miltenyi) according to manufacturer’s protocol. WT cells, B2m−/−Ciita−/− 
cells and B2m−/−Ciita−/− Cd47 tg cells were then incubated with the recombinant 
mouse NKp46 or NKG2D human Fc chimera protein or the recombinant control 
IgG1 Fc protein (R&D systems) for 45 min at 4 °C. FITC-conjugated anti-human 
IgG1 antibody (Invitrogen) served as secondary antibody. YAC-1 cells were 
used as positive control. Data analysis was carried out using flow cytometry (BD 
Bioscience) and FlowJo software, and results were expressed as fold change to the 
isotype-matched control Fc fusion protein.
Survival analysis of differentiated derivatives using BLI. For BLI, D-luciferin 
firefly potassium salt (375 mg kg−1; Biosynth) was dissolved in PBS (pH 7.4)  
(Gibco, Invitrogen) and was injected intraperitoneally (250 μl per mouse) into 
anesthetized mice. Animals were imaged using the IVIS 200 system (Xenogen). 
Region of interest (ROI) bioluminescence was quantified in units of maximum 
photons per second per centimeter square per steradian (p s−1 cm−2 sr−1). The 
maximum signal from an ROI was measured using Living Image software 
(MediaCybernetics). Mice were monitored on day 0, day 1 and every other day 
until day 30 and every 10 days afterwards.
Matrigel plugs: cell morphology for miECs, miSMCs or miCMs. Eight hundred 
thousand B2m−/−Ciita−/− Cd47 tg miECs, miSMCs or miCMs in 1:1 diluted 
Matrigel (Corning) were injected into allogeneic BALB/c mice. Matrigel plugs were 
recovered after 1, 2, 3, 4, 5, 6 and 8 weeks and fixed in 4% paraformaldehyde in PBS 
with 1% glutaraldehyde for 24 h. Samples were dehydrated, embedded in paraffin 
and cut into sections of 5 µm thickness. For histopathology, sections were stained 
with hematoxylin and eosin (Carl Roth) and images taken with an inverted light 
microscope. Origin of cells was demonstrated with immunofluorescence staining. 
Sections were rehydrated, and underwent antigen retrieval and blocking. Samples 
were incubated with antibodies against luciferase (ab21176), SMA (ab21027, 
Abcam), VE-Cadherin (SC-6458) or α-sarcomeric actinin (EA-53, Abcam) and a 
corresponding secondary antibody conjugated with AF488 or AF555 (Invitrogen). 
Cell nuclei were counterstained with DAPI and images taken with a Leica SP5 laser 
confocal microscope (Leica).
For co-staining experiments of miECs and immune cells, primary antibodies 
were used against VE-Cadherin (SC-6458, Sigma) and CD3 (ab16669, Abcam), 
followed by the corresponding secondary antibody conjugated with AF488 or 
AF555 (Invitrogen).
Generation of human iPSCs (hiPSCs). The Human Episomal iPSC Line was 
derived from CD34+ cord blood using a three-plasmid, seven-factor (SOKMNLT; 
SOX2, OCT4 (POU5F1), KLF4, MYC, NANOG, LIN28 and SV40L T antigen) 
EBNA-based episomal system by Thermo Scientific. This cell line has been shown 
to be free of all reprogramming genes. These hiPSCs have a normal XX karyotype 
and endogenous expression of pluripotent markers including Oct4, SOX2 and 
NANOG (as shown by RT–PCR) and OCT4, SSEA4, TRA-1-60 and TRA-1-81  
(as shown by immunofluorescence).
Gene editing of hiPSC. hiPSC underwent two gene-modification steps. 
In the first step, CRISPR technology was used for a combined targeting 
of the coding sequence of human B2M gene with the CRISPR sequence 
5′- CGTGAGTAAACCTGAATCTT-3′ and the coding sequence of human 
CIITA gene with the CRISPR sequence 5′-GATATTGGCATAAGCCTCCC-3′. 
Linearized CRISPR sequence with T7 promoter were used to synthesize gRNA 
as per the kit’s instructions (MEGAshortscript T7 Transcription Kit, Thermo 
Fisher). The obtained in vitro transcription (IVT) gRNA was then purified via 
the MEGAclear Transcription Clean-Up Kit. For IVT gRNA delivery, cells were 
electroporated with 300 ng IVT gRNA using a Neon electroporation system and 
the conditions 1,200 V, 30 ms, 1 pulse into hiPSC stably expressing Cas9. After 
electroporation, edited hiPSC were expanded for single cell seeding: hiPSC 
cultures were dissociated into single cells using TrypLE Express (Gibco) and 
stained with Alexa Fluor 488-conjugated anti-TRA-160 mAb and propidium 
iodide. A FACSAria II cell sorter (BD Biosciences) was used for the sorting 
and doublets and debris were excluded from seeding by selective gating on 
forward and side light scatter properties. Viable pluripotent cells were selected 
on the absence of propidium iodide and presence of Tra1-60 staining. Single 
cells were then expanded into full-size colonies, after which the colonies were 
tested for CRISPR editing by sequencing. CRISPR-mediated cleavage was 
assessed using the GeneArt Genomic Cleavage Detection Kit (Thermo Fisher) 
for testing of the initial edited pools. For screening of the isolated clones, 
genomic DNA was isolated from 1 × 106 hiPSCs and the B2M and CIITA 
genomic DNA regions were PCR amplified using AmpliTaq Gold 360 Master 
Mix and the primer sets forward: 5′-TGGGGCCAAATCATGTAGACTC 
-3′ and reverse: 5′-TCAGTGGGGGTGAATTCAGTGT-3′ for B2M as 
well as forward: 5′-CTTAACAGCGATGCTGACCCC-3′ and reverse: 
5′-TGGCCTCCATCTCCCCTCTCTT-3′ for CIITA. For TIDE analysis, the 
obtained PCR product was cleaned up (PureLink PCR Purification Kit, Thermo 
Fisher) and Sanger sequencing was performed for the prediction of indel 
frequency. After the confirmation of B2M and CIITA disruption, cells were further 
characterized through karyotype analysis and the TaqMan hiPSC Scorecard Panel 
(Thermo Fisher). The hiPSCs were found to be pluripotent and maintained a 
normal (46,XX) karyotype during the genome editing process.
In the second step, the CD47 cDNA was synthesized and the DNA was 
cloned into a lentiviral plasmid with an EFS promotor and puromycin resistance 
cassette. Cells were transduced with lentiviral stocks and 8 μg ml−1 of Polybrene 
(Thermo Fisher). Media was changed daily after transduction. Three days after 
transduction, cells were expanded and selected with 0.5 μg ml−1 of puromycin. 
After 5 days of antibiotic selection, antibiotic-resistant colonies emerged and were 
further expanded to generate stable pools. The expression of CD47 transcripts 
was confirmed by quantitative PCR. Pluripotency assay (TaqMan hPSC Scorecard 
Panel, Thermo Fisher) and karyotyping was performed again to verify the 
pluripotent status of the cells.
Teratoma assays to study iPSC survival in vivo. Six to eight week-old 
immunodeficient SCID-beige mice were used for transplantation of WT hiPSC 
or B2M−/−CIITA−/− CD47 tg hiPSCs. Here 1 × 107cells were resuspended in 100 µl 
saline solution and injected into the right thigh muscle of the mice. Teratomas were 
recovered, fixed in 4% paraformaldehyde, dehydrated, embedded in paraffin and 
cut into sections of 5 µm thickness. For histopathology, sections were rehydrated 
and stained with hematoxylin and eosin. Images were taken with an inverted light 
microscope. For immunofluorescence, slides underwent heat-induced antigen 
retrieval in a steamer with Dako antigen-retrieval solution (Dako), followed by 
antigen blocking with Image-iT FX signal enhancer solution (Invitrogen). Tissue 
sections were incubated with a primary antibody against brachyury (Ab20680, 
Abcam), followed by a goat anti-rabbit IgG secondary antibody conjugated 
with Alexa Fluor 555 (Invitrogen). Subsequently, sections were incubated with 
primary antibodies against cytokeratin 8 (EP1628Y, Abcam) and GFAP (GA5, 
Cell Signaling) conjugated with AF488 or AF647, respectively. DAPI was used to 
counterstain cell nuclei and images were acquired with a Leica SP5 laser confocal 
microscope (Leica).
Pluripotency analysis by RT–PCR and immunofluorescence. hiPSCs were plated 
in confocal dishes (MatTek) for immunofluorescence analysis 48 h after plating 
using the hiPSC Characterization Kit (Applied Stem Cell). Briefly, cells were fixed, 
permeabilized and stained overnight at 4 °C with the primary antibodies for OCT4, 
SOX2, SSEA4, TRA-1-60 and TRA-1-81 (Applied Stem Cell). After several washes, 
the cells were incubated with a secondary antibody and DNA staining solution. 
Alkaline phosphatase activity assay was performed (Applied Stem Cell). Stained 
cells were imaged using a fluorescent microscope.
For RT–PCR, RNA was extracted using the RNeasy Plus Mini Kit (Qiagen). 
Genomic DNA contamination was removed using the gDNA spin column. 
cDNA was generated using Applied Biosystems High-Capacity cDNA Reverse 
Transcription Kit. Gene-specific primers of the hiPSC Characterization Kit 
(Applied Stem Cell) were used to amplify target sequences Actin was used as 
housekeeping gene. PCR reactions were performed on Mastercycler nexus 
(Eppendorf) and visualized on 2% agarose gels.
Humanized mice. Humanized NSG-SGM3 mice (18–30 weeks) were purchased 
from Jackson Laboratories. Human CD34+ hematopoietic stem cell-engrafted 
NSG-SGM3 mice develop multi-lineage human immune cells, and demonstrate  
a functional human immune system displaying T cell-dependent immune 
responses with no donor cell immune reactivity towards the host. Animals 
were randomly assigned to experimental groups. The percentage of CD3+ cells 
among the human CD45+ cell population was assessed in every animal and CD3 
percentages were never significantly different between WT and B2M−/−CIITA−/− 
CD47 tg groups (Supplementary Fig. 13a). The number of animals per 
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experimental group is presented in each figure. All humanized NSG-SGM3 mice 
were HLA-A typed and the number of mismatches to the cell graft calculated 
(Supplementary Fig. 13b). In the Elispot assays with hiPSCs, there were 1.6 ± 0.5 
and 1.7 ± 0.5 (P = 0.61), with hiCMs 1.3 ± 0.6 and 1.3 ± 0.6 (P = 1) mismatches for 
WT and B2M−/−CIITA−/− CD47 tg, respectively, and in the hiEC groups there were 
always two mismatches. The mismatches for the BLI experiments are shown in 
Supplementary Fig. 10j.
All BLT mice were approved by the University of North Carolina at Chapel 
Hill Institutional Animal Care and Use Committee and were generated with the 
same human tissue using NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, Jackson 
Laboratories) and there were five out of six HLA class I and 4 out of 4 class II 
mismatches to the transplanted hiPSCs or derivatives. The percentage of CD3+ 
cells among the human CD45+ cell population was never significantly different 
between WT and B2M−/−CIITA−/− CD47 tg groups (Supplementary Fig. 13c). The 
percentage of CD3+ cells among the human CD45+ cell population was typically in 
the 15–65% range.
Human iPSC differentiation into hiECs. hiPSC were plated on diluted Matrigel 
(356231, Corning) in six-well plates and maintained in Essential 8 Flex media 
(Thermo Fisher). The differentiation was started at 60% confluency and media 
was changed to RPMI-1640 containing 2% B-27 minus insulin (both Gibco) and 
5 μM CHIR-99021 (Selleckchem). On day 2, the media was changed to reduced 
media: RPMI-1640 containing 2% B-27 minus insulin (Gibco) and 2 μM CHIR-
99021 (Selleckchem). From day 4 to 7, cells were exposed to RPMI-1640 EC media, 
RPMI-1640 containing 2% B-27 minus insulin plus 50 ng ml−1 human vascular 
endothelial growth factor (VEGF; R&D Systems), 10 ng ml−1 human fibroblast 
growth factor basic (FGFb; R&D Systems), 10 μM Y-27632 (Sigma-Aldrich), and 
1 μM SB 431542 (Sigma-Aldrich). Endothelial cell clusters were visible from day 
7 and cells were maintained in EGM-2 SingleQuots media (Lonza) plus 10% FCS 
hi (Gibco), 25 ng ml−1 VEGF, 2 ng ml−1 FGFb, 10 μM Y-27632 (Sigma-Aldrich) and 
1 μM SB 431542 (Sigma-Aldrich). The differentiation process was completed after 
14 days und undifferentiated cells detached during the differentiation process. For 
purification, cells were treated with 20 μM PluriSln-1 (StemCell Technologies) for 
48 h. The highly purified ECs were cultured in EGM-2 SingleQuots media (Lonza) 
plus supplements and 10% FCS hi (Gibco). TrypLE Express was used for passaging 
the cells 1:3 every 3–4 days.
Immunofluorescence staining was performed as described above to confirm 
their phenotype. Primary antibodies were used against CD31 (ab28364, Abcam) 
and VE-Cadherin (sc-6458, Santa Cruz Biotechnology), followed by the 
corresponding secondary antibody conjugated with AF488 or AF555 (Invitrogen). 
Cell nuclei were stained with DAPI. Imaging was performed using a Leica SP5 laser 
confocal microscope (Leica).
PCR for VE-Cadherin (forward: 5′-AAGATGCAGAGGCTCATG-3′, reverse: 
5′-CATGAGCCTCTGCATCTT-3′) was performed as described above.
Human iPSC differentiation into hiCMs. hiPSCs were plated on diluted Matrigel 
(356231, Corning) in six-well plates and maintained in Essential 8 Flex media 
(Thermo Fisher). Differentiation was started at 90% confluency, and media was 
changed to 5 ml of RPMI-1640 containing 2% B-27 minus Insulin (Gibco) and 
6 μM CHIR-99021 (Selleckchem). After 2 days, media was changed to RPMI-1640 
containing 2% B-27 minus insulin without CHIR. On day 3, 5 μl IWR1 was added 
to the media for two further days. At day 5, the media was changed back to RPMI-
1640 containing 2% B-27 minus insulin medium and left for 48 h. At day 7, media 
was changed to RPMI-1640 containing B27 plus insulin (Gibco) and replaced every 
3 days thereafter with the same media. Spontaneous beating of cardiomyocytes 
was first visible around day 10. Purification of cardiomyocytes was performed 
on day 10 post-differentiation. Briefly, media was changed to low glucose media 
and maintained for 3 days. At day 13, media was changed back to RPMI-1640 
containing B27 plus insulin. This procedure was repeated on day 14.
Immunofluorescence staining was performed as described above to confirm 
their phenotype. Primary antibodies were used against α-sarcomeric actinin  
(EA-53, Abcam) and troponin I (ab47003, Abcam), followed by the corresponding 
secondary antibody conjugated with AF488 or AF555 (Invitrogen). Cell nuclei 
were stained with DAPI. Imaging was performed using a Leica SP5 laser confocal 
microscope (Leica).
PCR for troponin (cTNT, forward: 5′-GAGGCACCAAGTTGGGCATGAACG 
A-3′, reverse: 5′-GGCAGCGGAAGAGGATGCTGAA′) was performed as 
described above.
Flow cytometry analysis. Human iPSCs, iCMs and iECs were plated in six-well 
plates in medium containing 100 ng ml−1 of IFN-γ. Cells were harvested and labeled 
with antibodies. APC-conjugated anti-HLA-A,B,C antibody (clone G46_2.6,BD 
Biosciences) or APC-conjugated IgG1 isotype-matched control antibody (clone 
MOPC-21,BD Biosciences). Alexa-flour647-labeled anti-HLA-DR,DP,DQ 
antibody (clone Tu3a, BD Biosciences) or Alexa-flour647-labeled IgG2a isotype-
matched control antibody (clone G155-178, BD Biosciences). PerCP-Cy5-
conjugated anti-CD47 (clone B6H12, BD Biosciences) or PerCP-Cy5-conjugated 
IgG1 isotype-matched control antibody (clone MOPC-21, BD Biosciences). Results 
were expressed as fold change to isotype-matched control Ig staining.
For the assessment of purity of hiPSC derivatives, antibodies against TRA-1-60 
(Thermo Fisher), VE-Cadherin (Santa Cruz) and Troponin I (Santa Cruz) were 
used. The hiECs and hiCMs were generated with a purity of >95%.
Human NK cell Elispot assays. Human NK cells were co-cultured with 
B2M−/−CIITA−/− or B2M−/−CIITA−/− CD47 tg hiPSC and their IFN-γ release was 
measured. Human NK cells were purchased from StemCell Technologies and were 
>99% CD3- and 95% CD56+. Flow cytometry revealed >95% NK cells and <5% 
other cells including myeloid cells. Donor cells were mitomycin-treated and used as 
stimulator cells. K562 cells (Sigma-Aldrich) served as positive control. Stimulator 
cells were incubated with NK cells (1:1) in RPMI-1640 containing 1% pen-strep 
and 1 ng ml−1 human IL-2 (Peprotech) for 24 h and IFN-γ spot frequencies were 
enumerated using an Elispot plate reader.
T cell Elispot using humanized mice. For uni-directional Elispot assays, recipient 
splenocytes were isolated from humanized mice 5 days after cell injection and 
used as responder cells. Cells were incubated for 24 h in vitro with 1 μg ml−1 
anti-CD3 and 1 μg ml−1 anti-CD28 before plated for Elispot Assay. Donor cells 
were mitomycin-treated (50 μg ml−1 for 30 min) and used as stimulator cells. One 
hundred thousand stimulator cells were incubated with 1 × 106 recipient responder 
splenocytes for 48 h and IFN-γ and IL-5 spot frequencies were enumerated using 
an Elispot plate reader.
DSA. Sera from recipient mice were de-complemented by heating to 56 °C for 
30 min. Equal amounts of sera and cell suspensions (5 × 106 per ml) were incubated 
for 45 min at 4 °C. Cells were labeled with FITC-conjugated goat anti-human IgM 
(BD Bioscience) and analyzed by flow cytometry (BD Bioscience).
Matrigel plugs: cell morphology. One million B2M−/−CIITA−/− CD47 tg hiECs or 
hiCMs in 1:1 pro survival scaffold, consisting of 50% (vol/vol) Matrigel (Corning), 
100 μM ZVAD (Millipore), 50 nM Bcl-Xl BH4 (Millipore), 200 nM cyclosporine 
A (Sigma-Aldrich), 100 ng ml−1 IGF-1 (Peprotech) and 50 μM Pinacidil (Sigma-
Aldrich) were injected into humanized NSG-SGM3 mice. Matrigel plugs were 
recovered after 2, 4, 6 and 8 weeks, fixed in 4% paraformaldehyde in PBS with 1% 
glutaraldehyde, dehydrated and embedded in paraffin. Sections of 5 µm thickness 
were cut. For immunofluorescence, sections were rehydrated and underwent 
antigen retrieval, followed by antigen blocking. After incubation with a primary 
antibody against luciferase (ab21176), VE-Cadherin (SC-6458) or α-sarcomeric 
actinin (EA-53, Abcam), sections were incubated with a corresponding secondary 
antibody conjugated with AF488 or AF555 (Invitrogen). DAPI was used to 
counterstain cell nuclei and images were obtained with a Leica SP5 laser confocal 
microscope (Leica).
BLI. For BLI, D-luciferin firefly potassium salt (375 mg kg−1) (Biosynth) dissolved 
in sterile PBS (pH 7.4) (Gibco, Invitrogen) was injected intraperitoneally (250 
μl per mouse) into anesthetized mice. Animals were imaged using the ami HT 
(Spectral Instruments Imaging) ROI bioluminescence was quantified in units of 
maximum photons per second per centimeter square per steradian (p s−1 cm−2 sr−1). 
The maximum signal from an ROI was measured using Living Image software 
(MediaCybernetics). Humanized mice were injected with 5 × 105 or 1 × 106 cells in 
pro survival scaffold as described above. Mice were monitored on day 0, day 1 and 
every 4 days until cells were rejected or up to 50 days.
In vitro NK cell killing. Mouse NK cells were isolated from fresh BALB/c  
or C57BL/6 spleens 18 h after poly I:C injection (100 μg intraperitoneally).  
After red cell lysis, NK cells were purified with MagniSort Mouse NK cell 
Enrichment Kit (Invitrogen), followed by CD49b MACS-sorting (Miltenyi).  
This cell population was highly selected for NK cells with a purity of >9%. Human 
NK cells from PBMCs were purchased from StemCell Technologies containing 
>99% NK cells.
NK cell killing assays were performed on the XCelligence SP platform (ACEA 
BioSciences). 96-well E-plates (ACEA BioSciences) were coated with collagen 
(Sigma-Aldrich) and 4 × 105 WT, B2m−/−Ciita−/−, or B2m−/−Ciita−/− Cd47 tg miECs 
or WT, B2M−/−CIITA−/− or B2M−/−CIITA−/− CD47 tg hiECs were plated in 100 μl 
cell-specific media containing 1 ng ml−1 mouse or human IL-2 (Peprotech). After 
the Cell Index value reached 0.7, NK cells were added with an effector cell / target 
cell (E/T) ratio of 0.5/1, 0.8/1 or 1/1. As a negative control, cell treated with 2% 
Triton X100 was used. Some wells were pretreated with mouse Cd47 or human 
CD47-blocking antibody (BioXCell) with 10 μg ml−1 media for 2 h. Data were 
standardized and analyzed with the RTCA software (ACEA).
NK cell stimulatory ligands. For the detection of NKG2D, NKp80, NKp46, 
NKp44 and NKp30 on hiPSCs, hiECs and hiCMs, cells were plated on gelatin-
coated six-well plates. K562 cells were plated in six-well plates as suspension cells. 
After harvesting, cells were blocked with human FcR blocking reagent (Miltenyi) 
according to manufacturer’s protocol. Cells were labeled with recombinant human 
NKG2D, Nkp80, Nkp46, Nkp44 or Nkp30 Fc chimera proteins or the recombinant 
control IgG1 Fc protein (all R&D Systems) for 45 min at 4 °C, followed by the 
secondary antibody IgG1 conjugated with FITC (Invitrogen). Data analysis was 
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carried out by Flow Cytometry (BD Bioscience) and results were expressed as fold 
change to isotype control.
Statistics. All data are expressed as mean ± s.d. or in box blot graphs showing 
the median and the minimum to maximum range. Intergroup differences were 
appropriately assessed by either an unpaired Student’s t-test or a one-way ANOVA 
with Bonferroni’s post-hoc test. Further information on experimental design and 
reagents is available in the Nature Research Reporting Summary linked to this article.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
All data supporting the findings of this study are available in the paper and its 
Supplementary Information files.
NATuRe BiOTeCHNOLOGy | www.nature.com/naturebiotechnology
1nature research  |  life sciences reporting sum
m
ary
June 2017
Corresponding author(s): Sonja Schrepfer
Initial submission Revised version Final submission
Life Sciences Reporting Summary
Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life 
science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list 
items might not apply to an individual manuscript, but all fields must be completed for clarity. 
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research 
policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist. 
?    Experimental design
1.   Sample size
Describe how sample size was determined. The sample size for the in vivo studies to achieve statistical significance was not 
calculated before the studies as the survival of the hypo-cells in the different  
models was unknown prior. It was reasoned that 5-10 mice per group in individual 
experiments would indicate valid efficacy. Sample sizes in vitro were determined 
by three or more samples for comparisons between one or multiple groups, 
followed by the statistical test. Again, the sample size to achieve statistical 
significance was not calculated before the studies for the reason described above.
2.   Data exclusions
Describe any data exclusions. No pre-established data exclusion method was used. 
3.   Replication
Describe whether the experimental findings were 
reliably reproduced.
The experimental findings can be reliably reproduced. Some key data generated by 
one co-author were repeated by other co-authors.
4.   Randomization
Describe how samples/organisms/participants were 
allocated into experimental groups.
All samples were number coded until the readout was finalized. The numbers were 
assigned prior to the experiment and determined the group/ treatment/ condition. 
Animals were number coded and assigned to a group prior to the surgical 
procedure. 
5.   Blinding
Describe whether the investigators were blinded to 
group allocation during data collection and/or analysis.
Group allocation for cell transplantations were performed by blinded investigators. 
For in vivo imaging and teratoma measurement, the investigators doing the 
readouts (Core Facility) were not blinded, but not familiar with the experimental 
setup of this study. For immunofluorescent images, the animal group that each 
cell type belonged to was unknown at the time to the individual doing the imaging.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
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6.   Statistical parameters 
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the 
Methods section if additional space is needed). 
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same 
sample was measured repeatedly
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one- or two-sided (note: only common tests should be described solely by name; more 
complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
?   Software
Policy information about availability of computer code
7. Software
Describe the software used to analyze the data in this 
study. 
FlowJo7 was used to analyze flow cytometric data. Prism7 or Excel 2010 was used 
for graphing and statistical analysis. LivingImage3.1 was used for quantification of 
bioluminescence imaging. Elispots were enumerated by Immunospot software. 
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made 
available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for 
providing algorithms and software for publication provides further information on this topic.
?   Materials and reagents
Policy information about availability of materials
8.   Materials availability
Indicate whether there are restrictions on availability of 
unique materials or if these materials are only available 
for distribution by a for-profit company.
No restriction. Standard MTA needed.
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9.   Antibodies
Describe the antibodies used and how they were validated 
for use in the system under study (i.e. assay and species).
The following antibodies were used for immunostaining: brachyury (polyclonal, 
catalog# ab20680, Abcam), cytokeratin 8 (clone: EP1628Y, AF488, 
catalog#ab192467), GFAP (clone: GA5, catalog#3670, Cell Signaling), CD31 
(polyclonal, catalog # ab28364, abcam), Ve-Cadherin (polyclonal, catalog# sc-6458, 
Santa Cruz Biotechnology), smooth muscle actin (polyclonal, catalog #ab21027, 
Abcam), sm22 (polyclonal, catalog #ab14106, Abcam), α-sarcomeric actinin (clone: 
EA-53, catalog# ab9465, Abcam), troponin I (polyclonal, catalog #ab47003, 
Abcam), luciferase (polyclonal, catalog #ab21176, abcam), CD3 (clone: SP7, catalog 
#ab16669, abcam). Following corresponding Secondary antibodies were used: 
donkey-anti-mouse IgG (polyclonal, AF555, catalog #A31570, Invitrogen), donkey-
anti-mouse IgG (polyclonal, AF488, catalog #A21202, Invitrogen), donkey-anti-
rabbit IgG (polyclonal, AF555, catalog #A31572, Invitrogen), donkey-anti-rabbit IgG 
(polyclonal, AF488, catalog #A21206, Invitrogen), goat-anti-rabbit IgG (polyclonal, 
AF555, catalog #A21430, Invitrogen), goat-anti-rabbit IgG (polyclonal, AF488, 
catalog #A11070, Invitrogen), goat-anti-mouse IgG (polyclonal, AF488, catalog 
#A11017, Invitrogen). 
 
For Flow cytometry analysis: MHC class I (clone AF6-88.5.5.3, PerCP-
eFlour710,catalog#46-5958-82, eBioscience), MHC class II (clone: M5/114.15.2, 
PerCP-eFlour710, catalog#46-5321-82,  eBioscience) Cd47 (clone: miap301, Alexa 
Fluor 647, catalog #563584, BD Biosciences), TRA-160 (clone XXX, ) HLA-A,B,C 
(clone G46_2.6, APC, catalog #562006, BD Biosciences), HLA-DR,DP,DQ (clone 
Tu3a,  AF647, catalog #563591, BD Biosciences), CD47 (clone B6H12, PerCP-Cy5, 
catalog #561261, BD Biosciences), VE-Cadherin (clone F-8, catalog #SC-9989, Santa 
Cruz Biotechnology), smooth muscle actin (polyclonal, catalog #ab5694, Abcam) 
and troponin I (clone CT3, PE, catalog #sc-20025, Santa Cruz). 
 
 
For NK-stimulation assays: NKG2D (catalog #1299-NK-050, R&D Systems), Nkp80 
(catalog #1900-NK-050, R&D Systems), Nkp46 (catalog #1850-NK-025, R&D 
Systems), Nkp44 (catalog #2249-NK-050, R&D Systems), or Nkp30 (catalog #1849-
NK-025, R&D Systems). 
 
 
Characterization of human pluripotent stem cells were conducted using the 
Applied stem cell Human ES/iPS Cell Characterization Kit (ASK-3006). Mouse 
pluripotent stem cells were characterized by Applied stem cell Mouse ES/iPS Cell 
Characterization Kit (ASK-3005). For cell selection TRA-1-60 Alexa Fluor™ 488 
Conjugate Kit for Live Cell Imaging (A25618, Invitrogen) was used.
10. Eukaryotic cell lines
a.  State the source of each eukaryotic cell line used. The Human Episomal iPSC Line was purchased from Thermo Fisher Scientific 
(Waltham, MA). Mouse iPSCs were reprogramed from C57BL/6 mice. Mouse YAC-1 
and human K-562 were purchased from ATCC (Manassas, VA) and used as controls 
in appropriate NK cell assays. Irradiated CF1 Mouse Embryonic Fibroblasts (MEFs) 
were used as feeder cells for mouse iPSCs and purchased from Thermo Fisher 
Scientific.
b.  Describe the method of cell line authentication used. None of the cell lines used have been authenticated.
c.  Report whether the cell lines were tested for 
mycoplasma contamination.
All cell lines were tested and negative for mycoplasma contamination using the 
Universal Mycoplasma test kit from ATCC.
d.  If any of the cell lines used are listed in the database 
of commonly misidentified cell lines maintained by 
ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used.
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?    Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
11. Description of research animals
Provide details on animals and/or animal-derived 
materials used in the study.
Male  C57BL/6J, BALB/cAnNCrl, SCID-beige (CBySmn.CB17-Prkdcscid/J) and NSG 
(NOD.Cg-Prkdc-scid IL2rg-tm1Wjl/SzJ mice 6-12 weeks of age and humanized NSG-
SGM3 mice 18-30 weeks were purchased from Jackson Laboratories (Bar Harbor, 
Maine, USA). All mice were maintained in pathogen-free, ventilated cages with 
irradiated food and autoclaved water at the University of California San Francisco 
(UCSF) or at the University Hamburg (HH). Experimental procedures were 
approved by the Institutional Animal Care and Use Committee (IACUC) at UCSF or 
the "Amt fuer Gesundheit und Verbraucherschutz" at HH. Mice were monitored 
daily and euthanized by CO2 asphyxiation and cervical dislocation prior to any signs 
of distress. BLT mice were generated at the University of North Carolina (UNC) and 
were approved by the local IACUC at UNC.
Policy information about studies involving human research participants
12. Description of human research participants
Describe the covariate-relevant population 
characteristics of the human research participants.
The study did not involve human subjects.
